Immuno-Oncology | Specialty

Experts Discuss Immunotherapy's Evolution in Bladder Cancer

July 15th 2017

The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.

Immunotherapy for Operable NSCLC

July 13th 2017

Novel Immunotherapy Combinations for NSCLC

July 13th 2017

Emerging Immunotherapies and Combinations for NSCLC

July 13th 2017

Unmet Needs: Sequencing After Immunotherapy in NSCLC

July 13th 2017

Questions Surrounding Therapeutic Sequencing for NSCLC

July 13th 2017

Immunotherapy for Relapsed/Refractory NSCLC

July 13th 2017

Early Experience; Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy for NSCLC

July 13th 2017

The Ever-Evolving Treatment Paradigm for NSCLC

July 13th 2017

Nivolumab Associated With Improved QoL in Head and Neck Cancer

July 13th 2017

Following treatment with single-agent nivolumab (Opdivo), patients with head and neck squamous cell carcinoma saw improved or stable quality of life scores.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Therapy Combinations May Become the Treatment of Choice in Ovarian Cancer

July 12th 2017

The future of treatment for ovarian cancer may lie in immunotherapy combinations with PARP inhibitors or checkpoint inhibitors.

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

July 12th 2017

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Published Ipilimumab/Nivolumab Data Highlight Activity in Metastatic RCC

July 12th 2017

Patients with metastatic renal cell carcinoma had an objective response rate of 40% and a 2-year overall survival rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016.

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

July 11th 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Findings Highlight Efficacy of Sipuleucel-T in African-American Men With Prostate Cancer

July 11th 2017

Oliver Sartor, MD, discusses the analysis of African-American men receiving sipuleucel-T for castrate-resistant prostate cancer compared with Caucasians, and the implications of this research.

Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer

July 11th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Dr. Plimack on Frontline Pembrolizumab for Urothelial Carcinoma

July 7th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the KEYNOTE-052 trial investigating pembrolizumab (Keytruda) in the frontline setting for patients with urothelial carcinoma.